PEDIATRIC PHASE I TRIAL AND PHARMACOKINETIC STUDY OF LGC1057

维甲酸类化合物如顺式维甲酸(RA)具有广泛的活性。 在正常组织中引起生长抑制和分化，在 在体外培养了一些儿科恶性肿瘤。在患者中，既有全反式- 维甲酸(ATRA)和13-顺式维甲酸已被使用，尽管 具有不同光谱的抗肿瘤功效。一些理论上的 考虑因素和一些实验室数据表明，9-顺式-RA可能比 作为一种抗肿瘤药物，它比其他维甲酸类化合物更有效。这项建议 采用标准的I期设计和药代动力学。

Retinoids such as cis-retinoic acid (RA) have a broad spectrum of activity in causing growth inhibition and differentiation in normal tissue and in a number of pediatric malignancies in vitro. In patients, both all-trans- retinoic acid (ATRA) and 13-cis-retinoic acid have been used, although with a different spectrum of anti-tumor efficacy. Some theoretic considerations and some laboratory data suggest that 9-cis-RA may be more potent than other of the retinoids as an anti-tumor agent. This proposal uses a standard phase I design and pharmacokinetics.